MedWatch

Novo Nordisk in search of new, solid business-area

The pharmaceutical-group is currently running tests on 4 hemophilia-drugs

Foto: Novo Nordisk / PR

The pharmaceutical-group Novo Nordisk, a world-leader within diabetes treatment, has taken a decisive step in its efforts to become a dominant factor on the market for the hemophilia-variants, hemophilia A and hemophilia B.

According to Danish newspaper Berlingske, referring to the web-site clinicaltrials.gov, Novo Nordisk has just this week begun phase-3 trials on another hemophilia-product, which means that the company now has 4 products for the treatment of hemophilia in the final phase of trials, informs the newspaper.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier